4 August 2022

Smith+Nephew's OXINIUM◊ Technology Tour of Change touches down at the Pro Football Hall of Fame during enshrinement weekend

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that the OXINIUM Technology Tour of Change mobile exhibit will make a stop at the Pro Football Hall of Fame during its enshrinement weekend in Canton, Ohio from August 4-6. As the official joint replacement technology of the Pro Football Hall of Fame, Smith+Nephew is committed to educating retired players, their families, and the community about the differences in material, design and technology to consider when selecting a hip or knee replacement. Smith+Nephew is partnering with the Hall of Fame Health network of Elite Care centers to ensure that patients including former professional football players across the country have access to Smith+Nephew products and technologies.

Over the past 20 years, in over two million cases, OXINIUM Technology has established itself as the best performing bearing with the lowest risk of revision in total hip arthroplasty (THA)1-4 at 9-17 years, alongside strong clinical performance in knees.5,6

Pro Football Hall of Famer, Elvin Bethea received an OXINIUM implant as part of a recent total hip replacement procedure. He commented, “OXINIUM Technology has turned my life, my body, and my whole world around. Having this implant gives me peace of mind and allows me to continue to do the things I enjoy.”

The Tour of Change is a 550 square foot mobile exhibit that will be setup at Fun Fest - a free, family-focused event area on the Pro Football Hall of Fame campus during enshrinement weekend. The exhibit is designed to provide players, healthcare professionals and the community with an opportunity to learn what makes OXINIUM Technology unique, how an implant is made, and how it has delivered strong clinical performance over time in both hip and knee replacements.1-6

Bruce Matthews, a Pro Football Hall of Famer who is an OXINIUM knee patient is similarly pleased with his results. “After a 19-year career in the NFL as an offensive lineman, my knees took a beating and became too painful to ignore. I’m confident that Smith+Nephew’s OXINIUM Technology was the best choice for me, especially as a larger guy.”

To learn more about how OXINIUM delivers the durability of metal, the wear resistance of ceramic, and corrosion resistance better than both7-16, please visit www.oxinium.com.






David Snyder

+1 978-749-1440





About Smith+Nephew

Smith+Nephew is a portfolio medical technology business focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people’s bodies and their self-belief by using technology to take the limits off living. We call this purpose ‘Life Unlimited’. Our 18,000 employees deliver this mission every day, making a difference to patients’ lives through the excellence of our product portfolio, and the invention and application of new technologies across our three global franchises of Orthopaedics, Sports Medicine & ENT and Advanced Wound Management.

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and generated annual sales of $5.2 billion in 2021. Smith+Nephew is a constituent of the FTSE100 (LSE:SN, NYSE:SNN). The terms ‘Group’ and ‘Smith+Nephew’ are used to refer to Smith & Nephew plc and its consolidated subsidiaries, unless the context requires otherwise.

For more information about Smith+Nephew, please visit www.smith-nephew.comand follow us on TwitterLinkedInInstagram or Facebook.



Forward-looking Statements

This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith+Nephew, these factors include: risks related to the impact of COVID-19, such as the depth and longevity of its impact, government actions and other restrictive measures taken in response, material delays and cancellations of elective procedures, reduced procedure capacity at medical facilities, restricted access for sales representatives to medical facilities, or our ability to execute business continuity plans as a result of COVID-19; economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers (including, without limitation, as a result of COVID-19); price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers (including, without limitation, as a result of COVID-19); competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith+Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith+Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith+Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith+Nephew are qualified by this caution. Smith+Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith+Nephew's expectations.




  1. Davis ET, Pagkalos J, Kopjar B. Bearing surface and survival of cementless and hybrid total hip arthroplasty in the National Joint Registry of England, Wales, Northern Ireland and the Isle of Man. JBJS. 2020;5(2):pe0075.
  2. Peters RM, Van Steenbergen LN, Stevens M, et al. The effect of bearing type on the outcome of total hip arthroplasty. Acta Orthopaedica. 2018; 89(2):163-169.
  3. Atrey A, Ancarani C, Fitch D, Bordini B. Impact of bearing couple on long-term component survivorship for primary cementless total hip replacement in a large arthroplasty registry. Poster presented at: Canadian Orthopedic Association; June 20–23, 2018; Victoria, British Columbia, Canada.
  4. Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) Hip, Knee & Shoulder Arthroplasty: 2021 Annual Report.
  5. The Orthopaedic Data Evaluation Panel (ODEP). www.odep.org.uk. Accessed June 1st, 2021. Referencing JOURNEY II, LEGION and GENESIS II OXINIUM Knee Systems.
  6. Innocenti M, Matassi F, Carulli C, Nistri L, Civinini C. Oxidized zirconium femoral component for TKA: A follow-up note of a previous report at a minimum of 10 years. The Knee. 2014;21:858–861.
  7. Hunter G, Dickinson J, Herb B, et al. Creation of oxidized zirconium orthopaedic implants. Journal of   ASTM International. 2005;2:1-14.
  8. Long M, Riester L, Hunter G. Nano-hardness Measurements of Oxidized Zr-2.5Nb and Various Orthopaedic Materials. Abstract presented at: 24th Annual Meeting of the Society for Biomaterials. April 22-26, 1998, San Diego, California.
  9. Parikh A, Hill P, Hines G, Pawar V. Wear of conventional and highly crosslinked polyethylene liners during simulated fast walking/jogging. Poster presented at: 55th Annual Meeting of the Orthopaedic Research Society, 2009. Poster no. 2340.
  10. Parikh A, Hill P, Pawar V, Sprague J. Long-term Simulator Wear Performance of an Advanced Bearing Technology for THA. Poster presented at: 2013 Annual Meeting of the Orthopaedic Research Society. Poster no. 1028.
  11. Papannagari R, Hines G, Sprague J, Morrison M. Long-term wear performance of an advanced bearing technology for TKA. Poster presented at: 2011 Annual Meeting of the Orthopaedic Research Society. Poster no. 1141.
  12. Smith+Nephew 2010. OR-10-155.
  13. Aldinger P, Williams T, Woodard E. Accelerated Fretting Corrosion Testing of Zirconia Toughened Alumina Composite Ceramic and a New Composition of Ceramicised Metal Femoral Heads. Poster presented at: 2017 Annual Meeting of the Orthopaedic Research Society. Poster no. 1037.
  14. Smith+Nephew 2016. OR-16-127.
  15. 2005 ASM International Engineering Materials Achievement Award.
  16. Dalal A, Pawar V, McAllister K, Weaver C, Hallab NJ. Orthopedic implant cobalt-alloy particles produce greater toxicity and inflammatory cytokines than titanium alloy and zirconium alloy-based particles in vitro, in human osteoblasts, fibroblasts, and macrophages. J Biomed Mater Res Part A. 2012;100A:2147-2158.